CVE-2025-61940
8.7
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N
Summary
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
Affected Software
| Vendor | Product | Version Range | Status |
|---|---|---|---|
| Mirion Medical | EC2 Software NMIS BioDose | 0 < 23.0 | affected |
| Mirion Medical | EC2 Software NMIS BioDose | 23.0 | unaffected |
Weaknesses
- CWE-603: CWE-603
ADP Enrichment
CISA ADP Vulnrichment
- SSVC:
- Exploitation: none
- Automatable: no
- Technical Impact: total
References
Feedback
Was this page helpful?
Glad to hear it! Please tell us how we can improve.
Sorry to hear that. Please tell us how we can improve.